CX-516
CX-516 is one of the first Ampakine compounds developed by Cortex Pharmaceuticals designed to enhance brain function and cognition. It is a nootropic compound, meaning it is specifically designed to improve cognitive function.
Pronunciation
CX-516 is pronounced as "C-X-five-sixteen".
Etymology
The term "CX-516" is a proprietary name given by Cortex Pharmaceuticals. The "CX" stands for "Cortex", and "516" is a unique identifier for the compound.
Function
CX-516 works by modulating the AMPA receptor, a type of glutamate receptor in the brain. By enhancing the activity of these receptors, CX-516 is believed to improve cognition and memory function.
Clinical Trials
CX-516 has been tested in clinical trials for its potential to treat Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). However, while it showed some promise, it was not significantly more effective than a placebo in improving cognition.
Related Compounds
Other Ampakine compounds developed by Cortex Pharmaceuticals include CX-546, CX-614, and CX-717. These compounds work in a similar way to CX-516, but have different chemical structures.
See Also
- AMPA receptor
- Glutamate receptor
- Nootropic
- Alzheimer's disease
- Schizophrenia
- Attention deficit hyperactivity disorder (ADHD)
External links
- Medical encyclopedia article on CX-516
- Wikipedia's article - CX-516
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski